Richard Beasley

Richard Beasley

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Richard Beasley

Medical Research Institute of New Zealand, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1995 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MAMi Asher
Mi Asher
UKU Keil
U Keil
HAHr Anderson
Hr Anderson
RBR Beasley
R Beasley
JCJ Crane
J Crane
AEAl. Et
Al. Et
The aetiology of asthma and allergic disease remains poorly understood, despite considerable research. The International Study of Asthma and Allergies in Childhood (ISAAC), was founded to maximize the value of epidemiological research into asthma and allergic disease, by establishing a standardized methodology and facilitating international collaboration. Its specific aims are: 1) to describe the prevalence and severity of asthma, rhinitis and eczema in children living in different centres, and to make comparisons within and between countries; 2) to obtain baseline measures for assessment of future trends in the prevalence and severity of these diseases; and 3) to provide a framework for further aetiological research into genetic, lifestyle, environmental, and medical care factors affecting these diseases. The ISAAC design comprises three phases. Phase 1 uses core questionnaires designed to assess the prevalence and severity of asthma and allergic disease in defined populations. Phase 2 will investigate possible aetiological factors, particularly those suggested by the findings of Phase 1. Phase 3 will be a repetition of Phase 1 to assess trends in prevalence.

6 April 2004 in Allergy
Verified
Journal Article
Closed access
PDF file
MMMatthew Masoli
Matthew Masoli
DFDenise Fabian
Denise Fabian
SHShaun Holt
Shaun Holt
RBRichard Beasley
Richard Beasley
GPGlobal Initiative for Asthma (GINA) Program
Global Initiative for Asthma (GINA) Program


1 September 2007 in Thorax
Verified
Journal Article
Open access
PDF file
NPNeil Pearce
Neil Pearce
NANadia Aït-Khaled
Nadia Aït-Khaled
RBRichard Beasley
Richard Beasley
JMJavier Mallol
Javier Mallol
UKUlrich Keil
Ulrich Keil
TGthe ISAAC Phase Three Study Group
the ISAAC Phase Three Study Group
Background: Phase I of the International Study of Asthma and Allergies in Childhood (ISAAC) was designed to allow worldwide comparisons of the prevalence of asthma symptoms. In phase III the phase I survey was repeated in order to assess changes over time. Methods: The phase I survey was repeated after an interval of 5–10 years in 106 centres in 56 countries in children aged 13–14 years (n = 304 679) and in 66 centres in 37 countries in children aged 6–7 years (n = 193 404). Results: The mean symptom prevalence of current wheeze in the last 12 months changed slightly from 13.2% to 13.7% in the 13–14 year age group (mean increase of 0.06% per year) and from 11.1% to 11.6% in the 6–7 year age group (mean increase of 0.13% per year). There was also little change in the mean symptom prevalence of severe asthma or the symptom prevalence measured with the asthma video questionnaire. However, the time trends in asthma symptom prevalence showed different regional patterns. In Western Europe, current wheeze decreased by 0.07% per year in children aged 13–14 years but increased by 0.20% per year in children aged 6–7 years. The corresponding findings per year for the other regions in children aged 13–14 years and 6–7 years, respectively, were: Oceania (−0.39% and −0.21%); Latin America (+0.32% and +0.07%); Northern and Eastern Europe (+0.26% and +0.05%); Africa (+0.16% and +0.10%); North America (+0.12% and +0.32%); Eastern Mediterranean (−0.10% and +0.79%); Asia-Pacific (+0.07% and −0.06%); and the Indian subcontinent (+0.02% and +0.06%). There was a particularly marked reduction in current asthma symptom prevalence in English language countries (−0.51% and −0.09%). Similar patterns were observed for symptoms of severe asthma. However, the percentage of children reported to have had asthma at some time in their lives increased by 0.28% per year in the 13–14 year age group and by 0.18% per year in the 6–7 year age group. Conclusions: These findings indicate that international differences in asthma symptom prevalence have reduced, particularly in the 13–14 year age group, with decreases in prevalence in English speaking countries and Western Europe and increases in prevalence in regions where prevalence was previously low. Although there was little change in the overall prevalence of current wheeze, the percentage of children reported to have had asthma increased significantly, possibly reflecting greater awareness of this condition and/or changes in diagnostic practice. The increases in asthma symptom prevalence in Africa, Latin America and parts of Asia indicate that the global burden of asthma is continuing to rise, but the global prevalence differences are lessening.

31 January 2016 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
AAAlvar Agustí
Alvar Agustí
EBElisabeth Bel
Elisabeth Bel
MTMike Thomas
Mike Thomas
CVClaus Vogelmeier
Claus Vogelmeier
GBGuy Brusselle
Guy Brusselle
IPIan D. Pavord
Ian D. Pavord
Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airway diseases that have a high personal and social impact. They likely represent a continuum of different diseases that may share biological mechanisms (i.e.endotypes), and present similar clinical, functional, imaging and/or biological features that can be observed (i.e.phenotypes) which require individualised treatment. Precision medicine is defined as “treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations”. In this Perspective, we propose a precision medicine strategy for chronic airway diseases in general, and asthma and COPD in particular.

20 December 2004 in Allergy
Verified
Journal Article
Closed access
PDF file
MHM. Humbert
M. Humbert
RBR. Beasley
R. Beasley
JAJ. Ayres
J. Ayres
RSR. Slavin
R. Slavin
JHJ. Hébert
J. Hébert
KSK. Surrey
K. Surrey